<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01720212</url>
  </required_header>
  <id_info>
    <org_study_id>178-CL-091</org_study_id>
    <nct_id>NCT01720212</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety and Plasma Concentration of YM178 OCAS Tablet (Mirabegron) in Healthy Chinese Volunteers</brief_title>
  <official_title>An Open-Label, Single and Multiple Dose Study to Assess the Safety and Pharmacokinetics of YM178 OCAS Tablet (Mirabegron) in Healthy Chinese Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma China, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and plasma concentration change of YM178 after single- and
      repeated-administration as oral absorption controlled tablet in healthy Chinese subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC of YM178 assessed by the plasma concentration changes</measure>
    <time_frame>Up to 96 hours after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of YM178 assessed by the plasma concentration changes</measure>
    <time_frame>Up to 96 hours after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of YM178 assessed by the plasma concentration changes</measure>
    <time_frame>Up to 96 hours after administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessment of YM178</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>Safety is to be assessed by the incidence of adverse events, vital signs, lab-tests and 12-lead ECGs</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Chinese Volunteers</condition>
  <arm_group>
    <arm_group_label>Single dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YM178</intervention_name>
    <description>oral</description>
    <arm_group_label>Single dose group</arm_group_label>
    <arm_group_label>Multiple dose group</arm_group_label>
    <other_name>Mirabegron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Body Mass Index (BMI) between 19 and 24, the weight is no less than 50 kg.

          2. Good health status

          3. The female subject must be either post-menopausal or surgically sterile. All women of
             child bearing potential will be required to use adequate contraception, must not be
             lactating, and must not be breastfeeding.

        Exclusion Criteria:

          1. The subject who has a known or suspected hypersensitivity to test drug or any of the
             constituents of the formulation used.

          2. Drug abusers and alcoholics.

          3. The subject who has consumed alcohol within 36 hours before administration.

          4. The subject who is positive for hepatitis B surface antigen (HBs- Ag) or hepatitis C
             virus (HCV) antibody.

          5. The subject who is positive for human immunodeficiency virus (HIV).

          6. The subject who consumes more than 1L tea and coffee per day.

          7. Smokers.

          8. The subject who has donated or lost over 200 mL blood

          9. The subject who has participated in other clinical trials

         10. The subject who has taken other drugs that prototype and its main metabolites had not
             completely eliminated

         11. The subject who has taken drugs repeatedly that may affect the metabolism of the test
             drug

         12. Psychopath.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2012</study_first_submitted>
  <study_first_submitted_qc>October 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2012</study_first_posted>
  <last_update_submitted>October 31, 2012</last_update_submitted>
  <last_update_submitted_qc>October 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>YM178</keyword>
  <keyword>Mirabegron</keyword>
  <keyword>OCAS</keyword>
  <keyword>Chinese Healthy Volunteers</keyword>
  <keyword>PK</keyword>
  <keyword>Safety</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

